Literature DB >> 25257104

Relaxin-3 receptor (Rxfp3) gene knockout mice display reduced running wheel activity: implications for role of relaxin-3/RXFP3 signalling in sustained arousal.

Ihaia T Hosken1, Steven W Sutton2, Craig M Smith1, Andrew L Gundlach3.   

Abstract

Anatomical and pharmacological evidence suggests the neuropeptide, relaxin-3, is the preferred endogenous ligand for the relaxin family peptide-3 receptor (RXFP3) and suggests a number of putative stress- and arousal-related roles for RXFP3 signalling. However, in vitro and in vivo evidence demonstrates exogenous relaxin-3 can activate other relaxin peptide family receptors, and the role of relaxin-3/RXFP3 signalling in specific brain circuits and associated behaviours in mice is not well described. In this study, we characterised the behaviour of cohorts of male and female Rxfp3 gene knockout (KO) mice (C57/B6J(RXFP3TM1/DGen)), relative to wild-type (WT) littermates to determine if this receptor KO strain has a similar phenotype to its ligand KO equivalent. Rxfp3 KO mice displayed similar performance to WT littermates in several acute behavioural paradigms designed to gauge motor coordination (rotarod test), spatial memory (Y-maze), depressive-like behaviour (repeat forced-swim test) and sensorimotor gating (prepulse inhibition of acoustic startle). Notably however, male and female Rxfp3 KO mice displayed robust and consistent (dark phase) hypoactivity on voluntary home-cage running wheels (∼20-60% less activity/h), and a small but significant decrease in anxiety-like behavioural traits in the elevated plus maze and light/dark box paradigms. Importantly, this phenotype is near identical to that observed in two independent lines of relaxin-3 KO mice, suggesting these phenotypes are due to the elimination of ligand or receptor and RXFP3-linked signalling. Furthermore, this behavioural characterisation of Rxfp3 KO mice identifies them as a useful experimental model for studying RXFP3-linked signalling and assessing the selectivity and/or potential off-target actions of RXFP3 agonists and antagonists, which could lead to an improved understanding of dysfunctional arousal in mental health disorders, including depression, anxiety, insomnia and neurodegenerative diseases.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Arousal; Neuropeptide receptor; RXFP3; Relaxin-3; Running wheel activity

Mesh:

Substances:

Year:  2014        PMID: 25257104     DOI: 10.1016/j.bbr.2014.09.028

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  15 in total

1.  Relaxin-3/RXFP3 signalling in mouse hypothalamus: no effect of RXFP3 activation on corticosterone, despite reduced presynaptic excitatory input onto paraventricular CRH neurons in vitro.

Authors:  C Zhang; D V Baimoukhametova; C M Smith; J S Bains; Andrew L Gundlach
Journal:  Psychopharmacology (Berl)       Date:  2017-03-17       Impact factor: 4.530

Review 2.  Modulation of forebrain function by nucleus incertus and relaxin-3/RXFP3 signaling.

Authors:  Francisco E Olucha-Bordonau; Héctor Albert-Gascó; Francisco Ros-Bernal; Valeria Rytova; Emma K E Ong-Pålsson; Sherie Ma; Ana M Sánchez-Pérez; Andrew L Gundlach
Journal:  CNS Neurosci Ther       Date:  2018-05-02       Impact factor: 5.243

Review 3.  Distribution, physiology and pharmacology of relaxin-3/RXFP3 systems in brain.

Authors:  Sherie Ma; Craig M Smith; Anna Blasiak; Andrew L Gundlach
Journal:  Br J Pharmacol       Date:  2016-12-04       Impact factor: 8.739

4.  Sensitivity to Chronic Methamphetamine Administration and Withdrawal in Mice with Relaxin-3/RXFP3 Deficiency.

Authors:  Mouna Haidar; Monica Lam; Berenice E Chua; Craig M Smith; Andrew L Gundlach
Journal:  Neurochem Res       Date:  2015-05-29       Impact factor: 3.996

Review 5.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

6.  Relaxin-3 receptor (RXFP3) signalling mediates stress-related alcohol preference in mice.

Authors:  Andrew W Walker; Craig M Smith; Berenice E Chua; Elena V Krstew; Cary Zhang; Andrew L Gundlach; Andrew J Lawrence
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

7.  GABAergic Neurons in the Rat Medial Septal Complex Express Relaxin-3 Receptor (RXFP3) mRNA.

Authors:  Hector Albert-Gascó; Sherie Ma; Francisco Ros-Bernal; Ana M Sánchez-Pérez; Andrew L Gundlach; Francisco E Olucha-Bordonau
Journal:  Front Neuroanat       Date:  2018-01-17       Impact factor: 3.856

Review 8.  Interactions of Circadian Rhythmicity, Stress and Orexigenic Neuropeptide Systems: Implications for Food Intake Control.

Authors:  Anna Blasiak; Andrew L Gundlach; Grzegorz Hess; Marian H Lewandowski
Journal:  Front Neurosci       Date:  2017-03-20       Impact factor: 4.677

9.  Targeted viral vector transduction of relaxin-3 neurons in the rat nucleus incertus using a novel cell-type specific promoter.

Authors:  Alexander D Wykes; Sherie Ma; Ross A D Bathgate; Andrew L Gundlach
Journal:  IBRO Rep       Date:  2019-12-13

10.  Therapeutic Targets and Mechanism of Xingpi Jieyu Decoction in Depression: A Network Pharmacology Study.

Authors:  Ze Chang; Li-Juan He; Dang-Feng Tian; Qiang Gao; Jing-Feng Ling; Yu-Chun Wang; Zhen-Yun Han; Rong-Juan Guo
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-23       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.